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Abstract
Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality and morbidity worldwide. This retrospective
observational study describes patient characteristics and hemostatic therapies administered to 352 parturients experiencing PPH
and analyzes risk factors for developing severe PPH. During the study period, bleeding was controlled in all cases and 99.4%
survived. The majority (98%) of patients received packed red blood cells. The most frequent hemostatic therapies administered
were fibrinogen concentrate (56%), fresh frozen plasma (49%), and platelets (30%). A total of 124 (35%) women experienced
severe PPH. Significant independent predictors for evolution to severe PPH were age, obstetric comorbidity, and plasma fibri-
nogen concentration. The latter was based on records from 267 (76%) patients. Plasma fibrinogen concentration before labor was
the only modifiable prepartum risk factor independently associated with severe PPH, indicating that fibrinogen monitoring is
warranted in these patients.
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Introduction
Postpartum hemorrhage (PPH) is a major contributor to maternal
death and severe maternal morbidity, leading to increased ther-
apeutic intervention, mechanical ventilation, hysterectomy, and
hospital stay.1-4 An increase in the prevalence of PPH has been
reported in several developed countries between 1991 and
2006.5-7 Despite the potentially severe outcomes of PPH, clinical
management is not evidence based and varies considerably
between centers. Protocols have been proposed for PPH manage-
ment8-11 but as yet there is little data reporting on their impact.
Postpartum hemorrhage can rapidly evolve to severe PPH,
variously defined as estimated total blood loss >1500 mL,12
>2000 mL,11 or >2500 mL13 within 24 hours of birth; transfu-
sion of 4 units12 or 5 units13 of blood; or a decrease in
hemoglobin levels4 g/dL.12 A number of risk factors for PPH
have been identified,14 but few have been specifically linked to
the evolution of severe PPH. However, plasma fibrinogen lev-
els have been linked to both the incidence and the severity of
PPH.15-17 The identification of prepartum characteristics that
highlight patients at risk of severe PPH before it occurs could
be clinically useful, although there is still some uncertainty
whether prepartum fibrinogen levels or any other prepartum
factors can predict evolution of PPH to severe PPH. For exam-
ple, one study found no association between elevated prepar-
tum fibrinogen levels and a reduced risk of PPH.18
Here, we present our experience of managing PPH in a
Spanish tertiary hospital with the main aim of describing
patients’ baseline characteristics and comorbidities, delivery
and hemorrhage characteristics, and hemostatic therapies admi-
nistered in line with our standardized treatment protocol, which
was carried out in cases of severe or massive hemorrhage. In
addition, we use our data to explore clinically important out-
comes in patients where PPH evolved to severe PPH and patients
where it did not. We also investigate prepartum characteristics
associated with the evolution of PPH to severe PPH.
Materials and Methods
Study Design and Patient Population
This was a retrospective, observational analysis of information
obtained from the general statistical data at La Paz University
Hospital, Madrid, between July 1, 2005, and December 31,
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2011. La Paz University Hospital is a tertiary referral hospital
with 9000 deliveries yearly, more than 25% of which are high-
risk parturients. All parturients experiencing PPH were eligible
for inclusion. The analysis was not designed as a case–control
study; data from parturients experiencing PPH were compared
with the general parturient population.
Critical Management of PPH
Patients were treated according to the multi-faceted, standar-
dized hospital protocol developed by us and described in
Guasch et al19 for use in severe or massive hemorrhage only,
as determined by the anesthesiologist. Following diagnosis,
surgical or medical control of the hemorrhage was initiated
by the consultant obstetricians. Blood samples were taken, and
4 units of packed red blood cells (pRBCs) were administered
immediately, followed by 4 g of fibrinogen concentrate, and
4 units of fresh frozen plasma (FFP). The decision to administer
pRBC and FFP was taken when bleeding appeared uncontrol-
lable, despite surgical attempts and when coagulopathy was
evidenced by analytical values or was suspected during the
hemorrhagic episode. If hemorrhage control was still insuffi-
cient, 4-factor prothrombin complex concentrate was adminis-
tered following consultation with a hematologist; with ongoing
life-threatening bleeding, activated recombinant factor VII
could also be administered. The decision was also taken as to
whether further steps to control the hemorrhage were required,
for example, embolization, laparotomy, hysterectomy, or other
surgical resource. Patients were divided into nonsevere
(defined as transfusion with <5 units pRBC) and severe PPH
(requiring 5 units pRBC). It was decided to base the defini-
tion on transfusion, rather than blood loss, as bleeding mea-
sures are frequently inaccurate.
Data Collection and Statistical Analyses
A broad range of demographic and pre-, peri-, and postpartum
data were collected from all parturients experiencing PPH until
discharge from the hospital. Prepartum coagulation measure-
ments were made using blood drawn directly before start of
labor, and the distributions were analyzed. Coagulation para-
meters were also recorded after hemorrhage and following
hemostatic therapy. Postoperative complications were identi-
fied as follows: acute kidney failure was defined as serum crea-
tinine levels greater than 1.2 mg/dL; acute pulmonary edema
was assessed by radiologic criteria and clinical features; acute
myocardial ischemia or infarction was identified by transient or
permanent electrocardiogram changes plus laboratory-
measured troponin I increase; urinary tract injury was defined
as damage to the ureter and/or bladder secondary to surgery;
and coagulopathy was measured by an activated partial throm-
boplastin time and/or international normalized ratio greater
than 1.5.
Categorical variables are summarized as the number
observed in each category (percentage of total population).
Continuous variables are presented as mean values (+
standard deviation) if normally distributed and median values
(interquartile range) otherwise. Fisher exact test was used to
compare outcomes between the nonsevere and the severe PPH
groups. Univariate and multivariate analyses were performed
to identify prepartum characteristics associated with evolution
to severe PPH. Two multivariate analyses were carried out:
Model 1 used only variables for which data were available for
85% of patients (and so did not include ethnicity, where the
patient was referred from, fibrinogen levels, or abnormal coa-
gulation), while Model 2 included variables with larger propor-
tion of missing data (data included as for Model 1, with the
addition of fibrinogen levels and abnormal coagulation).
Results
Patient Characteristics
A total of 56 984 women gave birth in our center during the
study period, of which 352 (0.62%) women were treated for
PPH; bleeding was controlled in all cases, and 99.4% of the
patients with PPH survived. Two fatalities were reported; the
first died after hepatic failure, while the second died following
acute respiratory distress syndrome arising due to an influenza
A H1N1 infection. The majority of patients with PPH were
referred from the delivery room (45%), other maternal hospital
ward (21%), the patient’s home (17%), the intensive care unit
(ICU; 9%), other hospitals (4%), or postdelivery wards (3%).
The baseline characteristics and comorbidities for patients
with PPH are summarized in Table 1. The number of multiple
births was relatively high in the PPH population (11% vs 3% in
the general parturients population), with a 4.3 times increase in
relative risk of multiple births in the PPH population (P < .001).
Delivery and hemorrhage characteristics are described in
Table 2. Almost 50% of patients with PPH required an emer-
gency cesarean delivery, with an increased relative risk of
2.0 (P < .001) in the PPH population compared to the general
parturients population. The most common reasons for emer-
gency cesarean section were fetal distress, placenta previa, or
repeat cesarean delivery. In comparison, 23% of patients with
PPH required instrumental delivery, with the most common
reasons being a long second stage or fetal distress. The gesta-
tional age was recorded for 336 patients and was found to be
full term in the majority of cases (236 deliveries, 70%), but pre-
term (24-36 weeks) in 68 (20%) patients, puerperal in 13 (4%)
patients, and not viable (<24 weeks) in 19 (6%) patients. Pre-
maturely ruptured membranes (>24 hours) were observed in
11 (3%) of 352 patients.
In the majority (92%) of patients, hemorrhage occurred fol-
lowing delivery but was also observed prenatally (10%), and
during the first (6%), second (6%), and third (10%) stages of
labor.
Coagulation Tests and Hemostatic Management
Patients were treated according to a standardized protocol; the
therapies administered for hemostatic management are sum-
marized in Table 3. The association between the amount of
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colloid and/or crystalloids administered and the occurrence of
renal failure was examined, and no relationship was found.
Coagulation parameters were recorded just before labor, after
hemorrhage (lowest values pre-transfusion), and after hemo-
static therapy (Figure 1). The mean (standard deviation, range)
values observed were as follows: hemoglobin levels were 11.7
(1.7, 5.9-16.2) g/dL before labor, 6.7 (1.3, 2.9-11.1) g/dL post-
hemorrhage, and 9.4 (1.1, 7.1-13.1) g/dL following therapy;
hematocrit was 35.1 (4.8, 3.6-49.3) % before labor, 19.8 (3.7,
8.2–35.2) % posthemorrhage, and 27.9 (3.3, 20.7-39.2) % fol-
lowing therapy; platelet levels were 225 (80, 15-484) c/mL
before labor, 153 (73, 5-489) c/mL posthemorrhage, and 154
(70, 41-766) c/mL following therapy; fibrinogen levels were
555 (146, 126-1000) mg/dL before labor, 327 (127, 80-756)
mg/dL posthemorrhage, and 440 (140, 151-945) mg/dL follow-
ing therapy.
Evolution of PPH to Severe PPH
A total of 124 (35%) women experienced severe PPH (requir-
ing 5 units pRBC). The key clinical outcomes for patients
with severe versus nonsevere PPH are listed in Table 4. The
results indicate that severe PPH is more likely to require a
change from regional to general anesthesia and is associated
with a more than 8-fold increase in patients requiring emboli-
zation as well as a more than 5-fold increase in the incidence
of hysterectomy. Patients with severe PPH also had a 50% lon-
ger median stay in the ICU (36 [24-58] hours vs 24 [12-30]
hours in the nonsevere PPH group). Before labor, mean (med-
ian, range) values for fibrinogen levels in all parturients were
555 (554, 126-1000) mg/dL and 568 (561, 204-1000) mg/dL
and 527 (547, 126-952) mg/dL in patients with nonsevere and
severe PPH, respectively.
Analyses were carried out to identify any prepartum risk
factors linked to the evolution of severe PPH. A univariate
analysis was performed to identify prepartum variables associ-
ated with increased odds of severe PPH (Table 5). A 5-year
Table 1. Patient Baseline Characteristics and Comorbidities.
Variable
Number of Patients
Variable Recorded
Mean (SD) or
Number (%)
Age, years 348 32.9 (6.0)
BMI, kg/m2 315 27.7 (4.7)
Ethnic group 226
White 115 (51%)
Hispanic 58 (26%)
Black 19 (8%)
Asian 18 (8%)
North African 11 (5%)
Other 5 (2%)
Parity 348
1 178 (51%)
2 97 (28%)
3 46 (13%)
4þ 27 (8%)
Multiple births 352 38 (11%)
In vitro fertilization 350 34 (10%)
Previous PPH 349 12 (3%)
Previous cesarean section 352 64 (18%)
Medical comorbidities 351
Hypertensiona 58 (17%)
Gestational diabetesb 29 (8%)
Previous abdominal surgery 24 (7%)
Othersc 74 (21%)
Hematological comorbiditiesd 351 28 (8%)
Bleeding comorbiditiesd 21 (6%)
Thrombotic comorbiditiese 7 (2%)
Jehovah’s witnessf 351 2 (0.6%)
Obstetric comorbidities 352
Dead fetus 23 (7%)
Myoma or malformation 21 (6%)
Othersg 41 (12%)
Abbreviations: BMI, body mass index; DVT, deep vein thrombosis; LMWH,
low-molecular-weight heparin; PPH, postpartum hemorrhage; SD, standard
deviation.
aIncludes gestational hypertension, preeclampsia, chronic hypertension.
bDiagnosis of glucose intolerance after week 24, which needs insulin for glyce-
mic control.
cIncludes respiratory, endocrine pathology, hepatitis B/C infection, pregesta-
tional diabetes, psychiatric, cardiac pathology, HIV infection, nephrotic syn-
drome, lupus, HELLP syndrome, hepatic failure, obesity, H1N1 infection,
syphilis, multiple sclerosis, polytraumatized, myotonic dystrophia.
dIncludes prepartum coagulopathy, thrombocytopenia, LMWH treatment, von
Willebrand, aplastic anemia, thalassemia.
eIncludes previous DVT, FV Leiden, Family DVT.
fAlthough Jehovah’s witness patients refused transfusion, they are included as
transfusion was recommended by the anesthesiologist.
gIncludes placenta previa, provoked abortion, curettages, APP (previous toco-
lytic therapy), conization, chorioamnionitis, cervical cancer.
Table 2. Delivery and Hemorrhage Characteristics.
Variable
Number of Patients
Variable Recorded Number (%)
Controlled pregnancya 351 232 (92)
Start of labor 329
Spontaneous 236 (72)
Induced 93 (28)
Elective cesarean scheduled 340 5 (1)
Emergency cesarean performed 340 167 (49)
Eutocic deliveryb 340 101 (30)
Instrumental delivery 340 77 (23)
Intrapartum oxytocinc 218 91 (42)
Primary cause of hemorrhage 228
Atony 68 (30)
Vaginal tears 46 (20)
Placental abruption 16 (7)
Retained placenta 45 (20)
Placenta previa 15 (7)
Placenta accreta 15 (7)
Uterine rupture 13 (6)
Otherd 10 (4)
Abbreviations: DIC, disseminated intravascular coagulation; IQR, interquartile
range.
aDefined as women who attended prenatal clinic on a regular basis.
bDefined as delivery in the delivery suite without additional obstetric help, for
example, forceps, vacuum, and so on.
cDefined as oxytocin use during labor for labor augmentation or induction.
dIncludes uterine inversion, wall hematoma, DIC, gastric ulcer.
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increase in age was associated with a 29% increased odds
ratio for severe PPH, obstetric comorbidity was associated
with a 2.4 times greater odds ratio of severe PPH, and coagu-
lation diagnosed as ‘‘abnormal’’ increased the odds ratio of
severe PPH by 2.8-fold. Conversely, a 50 mg/dL increase in
fibrinogen level resulted in a 10% reduction in the odds ratio
of severe PPH.
Multivariate analyses were also performed (Table 6). In
each case, age and obstetric comorbidity were still significant
independent predictors for evolution of PPH to severe PPH.
Plasma fibrinogen concentration directly before labor also
remained associated with severe PPH. However, abnormal coa-
gulation was not independently associated with severe PPH.
Discussion
In this study, we have presented our experience with 352 cases
of PPH, including 124 cases of severe PPH. Hemostasis was
restored in all cases and 99.4% of patients survived. Our
therapeutic approach combined standard transfusion practice
and coagulation factor concentrate-based therapy. This may
have improved the appropriateness of therapy received by each
patient and possibly explains the correction of hemostatic para-
meters observed posttherapy. However, new algorithms for the
effective management of PPH are under development, and it is
critical that these algorithms are widely tested, reported, disse-
minated, and applied in order to ensure the most appropriate
standardized practice.14
In our study, a small number of patients received tranexamic
acid (TXA); however, TXA was only introduced to our proto-
col in 2011, although it was occasionally administered prior to
this date at the hematologist’s discretion. Mounting evidence
suggests that TXA is useful for prevention and treatment of
PPH,20-22 and a global, multicenter, randomized, controlled
trial (the WOMAN trial) is underway to test the effects of TXA
on mortality and incidence of hysterectomy due to PPH.23
One-third of all cases evolved to severe PPH, which was
associated with a significantly higher rate of complications.
Several of these complications (eg, use of general anesthesia)
carry additional risks for the patient as well as incurring signif-
icant hospital costs. Additionally, hysterectomy means the
absolute loss of reproductive potential as well as being a major
surgical intervention. As such, the early identification and
treatment of women at risk of severe PPH may help minimize
the economic and psychological/socioeconomic costs associ-
ated with severe PPH.
The results of this retrospective analysis helped us identify
risk factors that may be used in the prepartum period to recog-
nize patients at risk of evolution of PPH to severe PPH. Inter-
estingly, some well-established risk factors for PPH, including
high parity, multiple births, previous cesarean section, and ane-
mia, were not significantly associated with the evolution of
PPH to severe PPH. The major risk factor for severe PPH was
the presence of an obstetric comorbidity; the most common
prepartum obstetric comorbidities in our population were dead
fetus, myoma, placenta previa, medically induced abortion, and
history of curettages in prior pregnancy. Physicians managing
patients with these conditions should prepare for rapid dete-
rioration of PPH to severe PPH and the need for intervention
to prevent hysterectomy. Age was the next factor most strongly
associated with severe PPH. As the average age of parturients is
increasing, the proportion of PPH episodes that evolve to
severe PPH may also increase.
Our findings build upon previous studies showing that
low prepartum fibrinogen is associated with increased inci-
dence of PPH, and low fibrinogen during PPH is associated
with evolution to severe PPH. The association of reduced
levels of fibrinogen with PPH severity indicates that fibrino-
gen replacement therapy may be a suitable addition to PPH
management. Data are limited, but fibrinogen concentrate
(in conjunction with other therapies) has been used as an
effective therapy for controlling PPH associated with low
fibrinogen levels.24,25 A trial is ongoing to evaluate whether
early treatment with fibrinogen concentrate reduces the need
for blood transfusion in women with severe PPH,26 and
Table 3. Volume Replacement, Transfusions, and Hemostatic
Therapies Administered.
Therapy Administered
Median (IQR) or Number (%)
All patients
With PPH
(N ¼ 352)
Patients With
Severe PPH
(N ¼ 124)
Crystalloid (Ringer’s solution)
Patients treated 290 (82%) 102 (82%)
Volume administered, mL 1500 (1000, 2500) 2000 (1500, 4000)
Colloid (HES: hydroxyethyl starch)
Patients treated 250 (71%) 95 (77%)
Volume administered, mL 1000 (500, 1000) 1000 (500, 1500)
pRBC
Patients treated 346 (98%) 124 (100%)
Dose administered, units 4 (2, 6) 8 (6, 11)
FFP
Patients treated 173 (49%) 119 (96%)
Dose administered, units 4 (3.5, 6) 6 (4, 7.5)
Platelets
Patients treated 106 (30%) 83 (67%)
Dose administered, units 2 (1, 3) 2 (1, 3)
Fibrinogen concentrate
Patients treated 196 (56%) 115 (93%)
Dose administered, g 4 (3, 4) 4 (4, 6)
Tranexamic acid
Patients treated 6 (2%) 3 (2%)
Dose administered, g 1 (1, 5.5) 1 (1, 2.5)
4-factor PCC
Patients treated 36 (10%) 31 (25%)
Dose administered, units 1500 (1000, 1500) 1500 (1000, 1500)
rFVIIa
Patients treated 29 (8%) 28 (23%)
Dose administered, mg 4.8 (4.0, 6.0) 4.8 (4.0, 6.0)
Abbreviations: FFP, fresh frozen plasma; IQR, interquartile range; N, number of
patients with data available; PCC, prothrombin complex concentrate; PP, post-
partum hemorrhage; pRBC, packed red blood cells; rFVIIa, activated recombi-
nant factor VII.
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Figure 1. Hematology and coagulation variables: Mean levels of (A) hemoglobin, (B) hematocrit, (C) platelets, and (D) fibrinogen and (E)
percentage of patients with normal coagulationa. aNormal coagulation defined as INR  1.5 and aPTT <1.5 times normal; N, number of patients
with data available. aPTT indicates activated partial thromboplastin time; INR, international normalized ratio; N, number of patients with data
available.
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fibrinogen replacement has been recommended as an early
intervention for the control of PPH associated with amniotic
fluid embolism.27
Low fibrinogen concentration directly before labor is the
only independent risk factor that we identified for severe PPH
that is readily modifiable indicating that early, targeted
Table 4. Outcomes Observed in Patients With Nonsevere Versus Severe PPH.
Variable
Nonsevere PPH, < 5 units
pRBC (N ¼ 228)
Severe PPH, 5 units
pRBC (N ¼ 124) P Value
Change from regional to general anesthetic, n (%) 12 (5%) 28 (23%) <.001
Embolization, n (%) 6 (3%) 32 (26%) <.001
Hysterectomy, n (%) 18 (8%) 52 (42%) <.001
Tracheal intubationa, n (%) 5 (2%) 44 (35%) <.001
Time in ICU, hours; median (IQR) 24 (12–30) 36 (24-58) <.001
Postoperative complications, n (%)
Free from complications 191 (84%) 76 (61%) <.001
Any complications 37 (16%) 48 (39%) <.001
Acute pulmonary edema 5 (2%) 12 (10%) .003
Acute kidney failure 9 (4%) 17 (14%) .001
Acute myocardial ischemia or infarction 3 (1%) 15 (12%) <.001
Others (including urinary injury) 25 (11%) 38 (31%) <.001
Abbreviations: ICU, intensive care unit; IQR, interquartile range; N, number of patients with data available; PPH, postpartum hemorrhage; pRBC, packed red blood
cells.
aDefined as postoperative ventilation.
Table 5. Univariate Analysis of Effects of Baseline Characteristics on Evolution of Severe PPH ( 5units pRBC).a
Variable N Category Severe PPH, n (%) Odds Ratio (95% CI) P Value
Age, yearsb 348 – – 1.29 (1.07-1.57) .009
BMIb 315 – – 0.82 (0.62-1.09) .17
Ethnicity 226 White 45/115 (39%) 1 .15
Hispanic 14/58 (24%) 0.49 (0.24-1.01)
Other 19/53 (36%) 0.87 (0.44-1.71)
Parity 348 1 55/178 (31%) 1 .10
2 35/97 (36%) 1.26 (0.75-2.13)
3þ 33/73 (45%) 1.85 (1.05-3.23)
Multiple births 352 No 110/314 (35%) 1 .83
Yes 14/38 (36%) 1.08 (0.54-2.18)
IVF 350 No 108/316 (34%) 1 .42
Yes 14/34 (41%) 1.35 (0.66-2.77)
Previous CS 352 No 100/288 (35%) 1 .67
Yes 24/64 (38%) 1.13 (0.64-2.00)
Hypertension 351 No 100/293 (34%) 1 .42
Yes 23/58 (40%) 1.27 (0.71-2.26)
Other medical comorbidity 351 No 84/244 (34%) 1 .72
Yes 39/107 (36%) 1.09 (0.68-1.76)
Hematological comorbidity 351 No 116/323 (36%) 1 .44
Yes 8/28 (29%) 0.71 (0.30-1.37)
Obstetric comorbidity 352 No 84/274 (31%) 1 .001
Yes 40/78 (51%) 2.38 (1.43-3.98)
Hemoglobin, g/dL 308 – – 1.00 (0.87-1.15) .99
Hematocrit, %b 304 – – 1.00 (0.78-1.28) .97
Platelets, c/mLc 195 – – 0.91 (0.75-1.11) .36
Fibrinogen, mg/dLc 267 – – 0.90 (0.83-0.99) .03
Coagulation 302 Normald 91/286 (32%) 1
Abnormald 9/16 (56%) 2.76 (0.99-7.63) .05
Abbreviations: aPTT, activated partial thromboplastin time; BMI, body mass index; CI, confidence interval; CS, cesarean section; INR, international normalized
ratio; IVF, in vitro fertilization; N, number of patients with data available; PPH, postpartum hemorrhage; pRBC, packed red blood cells.
aP values in bold indicate statistically significant values.
bOdds ratios given for a 5-unit increase in explanatory variable.
cOdds ratios given for a 50-unit increase in explanatory variable.
dNormal, INR 1.5 and aPTT <1.5 times normal; abnormal, INR >1.5 and aPTT 1.5 times normal.
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fibrinogen replacement therapy may be warranted during
severe PPH. Consistent with this, our data show a transfusion
pattern in which fibrinogen concentrate is frequently adminis-
tered during severe PPH. Fibrinogen concentrate was the only
available option that could elevate mean fibrinogen levels from
3.3 g/L to 4.4 g/L as observed in our population. As the fibri-
nogen content of FFP is only*2 g/L, it would not be suitable
to bring about this increase. Cryoprecipitate could be consid-
ered as an alternative to increase fibrinogen concentration in
this setting, but it was withdrawn from most European coun-
tries due to safety considerations.28
There are some limitations to this study: the findings are
subject to the constraints typically associated with retrospec-
tive data analyses, in particular the fact that full data were not
available for all patients. For example, we only had fibrinogen
data for 267 patients, representing 76% of the total study pop-
ulation. In addition, none of the analyses were prespecified, so
a sample size calculation was not performed to assess the sta-
tistical power of the study. Moreover, many of the comparative
analyses showed striking between-group differences with
highly significant P values. Generalizability of the findings is
also uncertain, given that our hospital is a tertiary referral cen-
ter, so may receive more serious cases of PPH compared with
other hospitals. Additionally, it should be noted that we did not
do a precise quantification of the amount of bleeding in our
patients with PPH.
In conclusion, our data describe successful management of
PPH in a tertiary hospital. Over 99% of the patients with PPH
survived. In our setting, the application of a multidisciplinary
protocol with early administration of fibrinogen and FFP was
useful in the absence of point-of-care viscoelastic measure-
ments such as thromboelastometry or thrombelastography. Pro-
tocols or guidelines for high-risk parturients are important in
this field, and plasma fibrinogen concentration directly before
labor was the only modifiable prepartum risk factor indepen-
dently associated with severe PPH. However, further study of
peripartum plasma fibrinogen levels is needed to examine the
role of fibrinogen. Close peripartum monitoring of fibrinogen
levels (or fibrin-based clotting) is warranted in line with the
2013 European Society of Anaesthesiology guidelines,8 espe-
cially in older parturients with obstetric comorbidities, as the
results indicate that these patients are at risk of severe PPH.
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